| Demo by Shiva |
|
Demo by Shiva |
|
24 hours |
| Day - 1 : Safety-Listings |
|
16.2.1.1 Assignment to Analysis Populations |
|
24 hours |
| Day - 2 : Safety-Listings |
|
16.2.1.3 Study Visits |
|
24 hours |
| Day - 3 : Safety-Listings |
|
16.2.1.5 Withdrawals from the Study |
|
24 hours |
| Day - 4 : Safety-Listings |
|
16.2.1.7 Abnormal Biochemistry Values |
|
24 hours |
| Day - 5 : Safety-Listings |
|
16.2.1.9 Vital Signs |
|
24 hours |
| Day - 6 : Safety-Listings |
|
16.2.2.3 Serious Adverse Events |
|
24 hours |
| Day - 7 : Safety-Tables |
|
14.1.1 Subject Assignment to Analysis Populations |
|
24 hours |
| Day - 8 : Safety-Tables |
|
14.1.4 Subject Disposition by Treatment (Safety Population) |
|
24 hours |
| Day - 9 : Safety-Tables |
|
14.1.6 Subject Demographics – Age (Safety Population) |
|
24 hours |
| Day - 10 : Safety-Tables |
|
14.1.8 Subject Demographics (Safety Population) |
|
24 hours |
| Day - 11 : Safety-Tables |
|
14.1.11 Subject Demographics -Sex and Race (Safety Population) |
|
24 hours |
| Day - 12 : Safety-Tables |
|
14.1.14 Treatment Emergent Adverse Events by Treatment, System Organ Class and Preferred Term (Safety Population) |
|
24 hours |
| Day - 13 : Safety-Tables |
|
14.1.16 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population) |
|
24 hours |
| Day - 14 : Safety-Tables |
|
14.1.18 Shift Table from Baseline to End of period (Safety Population) |
|
24 hours |
| Day - 15 : Safety-Tables |
|
14.1.20 Medical History by Treatment, System Organ Class and Preferred Term (Safety Population) |
|
24 hours |
| Day - 16 : Efficacy-Tables |
|
14.1.22 Best overall response (Safety Population) |
|
24 hours |
| Day - 17 : Efficacy-Tables |
|
14.1.24 Survival Estimates (Safety Population) |
|
24 hours |
| Day - 18 : Safety & Efficacy Figures/Graphs |
|
16.1.1 Creatinine (umol/L) Level by Age Range (Safety Population) |
|
24 hours |
| Day - 19 : Safety & Efficacy Figures/Graphs |
|
16.2.1 Distribution of Blood Pressure (safety Population) |
|
24 hours |
| Day - 20 : Safety & Efficacy Figures/Graphs |
|
Table 16.1.3 Distribution of Maximum Liver Function Test Values by Treatment (safety population) AND Kaplan-Meier Survival Plot (enrolled population) |
|
24 hours |
| Day - 21 : Safety-ADAM Data Sets |
|
ADAM OVERVIEW |
|
24 hours |
| Day - 22 : Safety-ADAM Data Sets |
|
ADSL PART-03 |
|
24 hours |
| Day - 23 : Safety-ADAM Data Sets |
|
ADSL PART 04 |
|
24 hours |
| Day - 24 : Safety-ADAM Data Sets |
|
ADSL FINAL PART & ADDV |
|
24 hours |
| Day - 25 : Safety-ADAM Data Sets |
|
ADAE |
|
24 hours |
| Day - 26 : Safety-ADAM Data Sets |
|
ADAE |
|
24 hours |
| Day - 27 : Safety-ADAM Data Sets |
|
ADCM |
|
24 hours |
| Day - 28 : Safety-ADAM Data Sets |
|
ADMH |
|
24 hours |
| Day - 29 : Safety-ADAM Data Sets |
|
ADVS |
|
24 hours |
| Day - 30 : Safety-ADAM Data Sets |
|
ADVS |
|
24 hours |
| Day - 31 : Efficacy-ADAM Data Sets |
|
ADRS |
|
24 hours |
| Day - 32 : Efficacy-ADAM Data Sets |
|
ADRS |
|
24 hours |
| Day - 33 : Efficacy-ADAM Data Sets |
|
ADTTE |
|
24 hours |
| Day - 34 : Safety-SDTM Data Sets |
|
SDTM OVERVIEW & TRAIL DOMAINS |
|
24 hours |
| Day - 35 : Safety-SDTM Data Sets |
|
DM |
|
24 hours |
| Day - 36 : Safety-SDTM Data Sets |
|
DM |
|
24 hours |
| Day - 37 : Safety-SDTM Data Sets |
|
DM |
|
24 hours |
| Day - 38 : Safety-SDTM Data Sets |
|
AE |
|
24 hours |
| Day - 39 : Safety-SDTM Data Sets |
|
AE |
|
24 hours |
| Day - 40 : Safety-SDTM Data Sets |
|
MH |
|
24 hours |
| Day - 41 : Safety-SDTM Data Sets |
|
CM & SUPP CM |
|
24 hours |
| Day - 42 : Safety-SDTM Data Sets |
|
TU |
|
24 hours |
| Day - 43 : Efficacy-SDTM Data Sets |
|
TR |
|
24 hours |
| Day - 44 : Extra Topics |
|
Define.Xml ,Pinnacle 21 ,Validation Of Tfl |
|
24 hours |
| Day - 45 : Extra Topics |
|
Material Related Interview Questions, Iss Ise Overview, Population Flags, Resumes &Tips |
|
24 hours |
